Product
Durvalumab + Olaparib
1 clinical trial
9 indications
Indication
Breast NeoplasmsIndication
Breast CancerIndication
Breast TumorsIndication
AngiosarcomaIndication
Triple-Negative Breast CancerIndication
Breast Cancer (HER2-positive)Indication
Hormone Receptor Positive TumorIndication
Hormone Receptor Negative TumorIndication
Locally Advanced Breast CancerClinical trial
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)Status: Recruiting, Estimated PCD: 2030-12-01